Grass Pollen Allergy - Pipeline Review, H2 2014

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Grass Pollen Allergy Overview 7
Therapeutics Development 8
Pipeline Products for Grass Pollen Allergy - Overview 8
Pipeline Products for Grass Pollen Allergy - Comparative Analysis 9
Grass Pollen Allergy - Therapeutics under Development by Companies 10
Grass Pollen Allergy - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Grass Pollen Allergy - Products under Development by Companies 14
Grass Pollen Allergy - Companies Involved in Therapeutics Development 15
ALK-Abello A/S 15
Allergy Therapeutics plc 16
Anergis SA 17
Biomay AG 18
BioTech Tools s.a. 19
Circassia Pharmaceuticals plc 20
HAL Allergy BV 21
Laboratorios LETI S.L. 22
Roxall Medizin GmbH 23
Grass Pollen Allergy - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
AllerG - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Allergen Extract Of Phleum Pratense - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Avanz Phleum Pratense - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
BM-32 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
clustoid wiesenlieschgras - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
gpASIT + TM - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Grass-SPIRE - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Oligonucleotide for Grass Allergy - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Pollinex Quattro Grass - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Timothy Grass Pollen Allergen Extract - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Vaccine for Grass Allergy - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Grass Pollen Allergy - Recent Pipeline Updates 48
Grass Pollen Allergy - Dormant Projects 52
Grass Pollen Allergy - Product Development Milestones 53
Featured News & Press Releases 53
Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK 53
Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study 53
Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 54
Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 54
Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK 55
Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet 55
Dec 06, 2013: Ethical committee of the University of Leuven approves a follow-up of the Phase IIa clinical study BTT006 to confirm a 2 years lasting immunological impact of 5 injections of gp-ASIT+TM 56
Nov 18, 2013: Update on Biotech Tools Phase IIa clinical study in the grass pollen allergy therapy 57
Nov 09, 2013: Merck's Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study 57
Oct 23, 2013: FDA reschedules Advisory Committee meeting for grass AIT tablet 59
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Number of Products under Development for Grass Pollen Allergy, H2 2014 8
Number of Products under Development for Grass Pollen Allergy - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Grass Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2014 15
Grass Pollen Allergy - Pipeline by Allergy Therapeutics plc, H2 2014 16
Grass Pollen Allergy - Pipeline by Anergis SA, H2 2014 17
Grass Pollen Allergy - Pipeline by Biomay AG, H2 2014 18
Grass Pollen Allergy - Pipeline by BioTech Tools s.a., H2 2014 19
Grass Pollen Allergy - Pipeline by Circassia Pharmaceuticals plc, H2 2014 20
Grass Pollen Allergy - Pipeline by HAL Allergy BV, H2 2014 21
Grass Pollen Allergy - Pipeline by Laboratorios LETI S.L., H2 2014 22
Grass Pollen Allergy - Pipeline by Roxall Medizin GmbH, H2 2014 23
Assessment by Monotherapy Products, H2 2014 24
Assessment by Combination Products, H2 2014 25
Number of Products by Stage and Target, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 28
Number of Products by Stage and Molecule Type, H2 2014 30
Grass Pollen Allergy Therapeutics - Recent Pipeline Updates, H2 2014 48
Grass Pollen Allergy - Dormant Projects, H2 2014 52 

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy